Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Cash & Equivalents (2020 - 2026)

Treace Medical Concepts filings provide 6 years of Cash & Equivalents readings, the most recent being $10.7 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 5.66% to $10.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.7 million, a 5.66% decrease, with the full-year FY2025 number at $10.7 million, down 5.66% from a year prior.
  • Cash & Equivalents hit $10.7 million in Q4 2025 for Treace Medical Concepts, up from $7.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $119.6 million in Q2 2021 to a low of $7.3 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $13.4 million (2025), compared with a mean of $38.1 million.
  • Biggest five-year swings in Cash & Equivalents: surged 1060.81% in 2021 and later plummeted 88.15% in 2023.
  • Treace Medical Concepts' Cash & Equivalents stood at $105.8 million in 2021, then plummeted by 81.6% to $19.5 million in 2022, then tumbled by 33.33% to $13.0 million in 2023, then dropped by 12.57% to $11.4 million in 2024, then fell by 5.66% to $10.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $10.7 million (Q4 2025), $7.7 million (Q3 2025), and $8.1 million (Q2 2025) per Business Quant data.